Cost-Effectiveness of Induction Treatment with Bortezomib Added to Thalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation in Germany
| Autor: | J. Diels, D. Wirth, Sophia E. Marsh, J.J. Lahuerta, J F San Miguel, Laura Rosiñol, S. Gaugris, C. van Beurden-Tan, M. Spencer, M. Treur, O. Chirita, J. Bladé |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Bortezomib Cost effectiveness Health Policy Public Health Environmental and Occupational Health Newly diagnosed medicine.disease Thalidomide Autologous stem-cell transplantation Internal medicine medicine business INDUCTION TREATMENT Dexamethasone Multiple myeloma medicine.drug |
| Zdroj: | Value in Health. 16:A409-A410 |
| ISSN: | 1098-3015 |
| DOI: | 10.1016/j.jval.2013.08.498 |
| Popis: | Van Beurden-Tan C1, Rosinol L2, Diels J3, Wirth D4, Chirita O5, Lahuerta JJ6, Gaugris S5, Marsh S5, San Miguel J7, Spencer M5, Treur M1 and Blade J2 1Pharmerit International, Rotterdam, The Netherlands, 2Hospital Clinic de Barcelona, Barcelona, Spain, 3Janssen Pharmaceutica NV, Beerse, Belgium, 4Janssen-Cilag GmbH, Germany, 5Janssen-Cilag Limited, United Kingdom, 6Hospital Universitario 12de Octubre, Madrid, Spain 7Hospital Clinico Universitario de Salamanca, Salamanca, Spain |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect